-
公开(公告)号：US20250134968A1
公开(公告)日：2025-05-01
申请号：US19015746
申请日：2025-01-10
Applicant: Protalix Ltd.
Inventor： Einat ALMON , Raul CHERTKOFF , Sari ALON , Yoseph SHAALTIEL
Abstract: Methods of treating Fabry disease via administration of stabilized plant recombinant human alpha galactosidase protein comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety, and unit dosages of protein are disclosed herein. The disclosed protocols are safe, have greater than 2 week intervals between administrations and exhibit important improvement in patient's disease parameters, in terms of reduced Gb3 accumulation, pain and GI parameters, kidney and cardiac stabilization in the clinical setting.
-
公开(公告)号：US20240002814A1
公开(公告)日：2024-01-04
申请号：US18035149
申请日：2021-11-03
Applicant: Protalix Ltd.
Inventor： Ilya RUDERFER , Yakir NATAF , Gil ARVATZ , Uri HANANIA , Tamar ARIEL , Shelly ROZEN , Yael HAYON
CPC classification number: C12N9/0048 , A61K38/44 , C12Y107/03003
Abstract: A modified uricase is described herein, as well as a method of reducing a level of uric acid by contacting a medium with the modified uricase. The modified uricase comprises a uricase polypeptide crosslinked by at least one bifunctional linking moiety that comprises a poly(alkylene glycol) moiety. A molecular weight of the bifunctional linking moiety is from about 1.5 kDa to about 4 kDa, and/or the modified uricase comprises a plurality of polypeptides having the amino acid sequence SEQ ID NO: 2. Further described is a polypeptide having the amino acid sequence SEQ ID NO: 2. A process of preparing the modified uricase is also described, comprising contacting the polypeptide with a crosslinking agent that comprises a poly(alkylene glycol) moiety and at least two aldehyde groups, to obtain a conjugate; and contacting the conjugate with a reducing agent.
-
公开(公告)号：US20230074255A1
公开(公告)日：2023-03-09
申请号：US17716348
申请日：2022-04-08
Applicant: Protalix Ltd.
Inventor： Avidor Shulman , Ilya Ruderfer , Tehila Ben-Moshe , Talia Shekhter , Yaniv Azulay , Tali Kizhner , Yoseph Shaaltiel
IPC: C12N9/40
Abstract: Multimeric protein structures comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety are disclosed herein, as well a process for preparing same, and methods of treating Fabry disease via administration of a multimeric protein structure. The disclosed multimeric protein structures exhibit an improved performance, in terms of enhanced activity and/or a longer lasting activity under both lysosomal conditions and in a serum environment.
-
公开(公告)号：US20230022576A1
公开(公告)日：2023-01-26
申请号：US17777669
申请日：2019-11-19
Applicant: Protalix Ltd.
Inventor： Maor SHEVA , Uri HANANIA
Abstract: A nucleic acid construct is disclosed which is removable after transformation. Methods of using same are disclosed as well.
-
公开(公告)号：US20240263150A1
公开(公告)日：2024-08-08
申请号：US18429649
申请日：2024-02-01
Applicant: Protalix Ltd.
Inventor： Ilya RUDERFER , Yakir NATAF , Gil ARVATZ , Uri HANANIA , Tamar ARIEL , Shelly ROZEN , Yael HAYON , Zohar KEREN , Orit COHEN-BARAK
IPC: C12N9/06 , A61K9/00 , A61K31/519
CPC classification number: C12N9/0048 , A61K9/0019 , A61K31/519
Abstract: A method of treating a disease or disorder associated with excessive uric acid levels is disclosed herein. The method comprises administering to the subject by i.v. infusion an amount of a recombinant homotetrameric uricase enzyme comprising four uricase polypeptides having the amino acid sequence as set forth in SEQ ID NO: 2, wherein the polypeptides are crosslinked by polyethylene glycol (PEG) bis-aldehyde having a molecular weight of 2-3.5 kDa.
-
Patent Agency Ranking
公开(公告)号：US20200155654A1
公开(公告)日：2020-05-21
申请号：US16476084
申请日：2018-01-05
Applicant: Protalix Ltd.
Inventor： Einat ALMON , Raul CHERTKOFF , Sari ALON , Yoseph SHAALTIEL
Abstract: Methods of treating Fabry disease via administration of stabilized plant recombinant human alpha galactosidase protein comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety, and unit dosages of protein are disclosed herein. The disclosed protocols are safe, have greater than 2 week intervals between administrations and exhibit important improvement in patient's disease parameters, in terms of reduced Gb3 accumulation, pain and GI parameters, kidney and cardiac stabilization in the clinical setting.
-
7.发明申请公开(公告)号：US20180327476A1
公开(公告)日：2018-11-15
申请号：US16045848
申请日：2018-07-26
Applicant: Protalix Ltd.
Inventor： Yoseph SHAALTIEL , Uri HANANIA , Tali KIZHNER , Tami ARIEL , Svetlana GINGIS-VELITSKI
IPC: C07K14/705 , C12N15/82 , A61K36/81 , A61K38/17 , C07K14/415 , C07K14/525 , C07K14/715 , C12N5/04 , C12N5/14 , C12N15/09 , C12N15/62 , C12N5/10
Abstract: A plant produced chimeric polypeptide is provided. The plant produced chimeric polypeptide comprising: (i) a first domain which comprises a TNF Alpha binding domain of a TNF receptor, and (ii) a second domain which comprises an Fc domain of an immunoglobulin, wherein the first domain and the second domain are N-terminally to C-terminally respectively sequentially translationally fused and wherein the chimeric polypeptide specifically binds TNF Alpha.
-
8.发明申请公开(公告)号：US20160075754A1
公开(公告)日：2016-03-17
申请号：US14849963
申请日：2015-09-10
Applicant: Protalix Ltd.
Inventor： Yoseph SHAALTIEL , Uri Hanania , Tali Kizhner , Tami Ariel , Svetlana Gingis-Velitski , Myriam Golembo
IPC: C07K14/705
CPC classification number: C07K14/7151 , A61K36/00 , A61K38/1793 , C07K2319/02 , C07K2319/30 , C12N15/8257
Abstract: A plant produced chimeric polypeptide is provided. The plant produced chimeric polypeptide comprising:(i) a first domain which comprises a TNF Alpha binding domain of a TNF receptor, and (ii) a second domain which comprises an Fc domain of an immunoglobulin, wherein the first domain and the second domain are N-terminally to C-terminally respectively sequentially translationally fused and wherein the chimeric polypeptide specifically binds TNF Alpha.
Abstract translation: 提供植物产生的嵌合多肽。 植物产生嵌合多肽，其包含：（i）包含TNF受体的TNFα结合结构域的第一结构域，和（ii）包含免疫球蛋白Fc结构域的第二结构域，其中第一结构域和第二结构域是 N末端至C末端分别顺序翻译融合并且其中所述嵌合多肽特异性结合TNFα。
-
9.发明申请USE OF PLANT CELLS EXPRESSING A TNFalpha POLYPEPTIDE INHIBITOR IN THERAPY 审中-公开植物细胞在治疗中表达TNFα多肽抑制剂的应用公开(公告)号：US20160017019A1
公开(公告)日：2016-01-21
申请号：US14773349
申请日：2014-03-06
Inventor： Yaron ILAN , Yoseph SHAALTIEL , Uri HANANIA , Tali KIZHNER , Tami ARIEL , Svetlana GINGIS-VELITSKI
IPC: C07K14/705 , A61K9/00 , A61K36/81 , C12N15/82 , C07K16/24
CPC classification number: C07K14/70578 , A61K9/0053 , A61K36/81 , A61K38/00 , C07K14/525 , C07K16/241 , C07K2317/14 , C07K2317/76 , C07K2319/30 , C07K2319/74 , C12N15/8257 , C12N15/8258
Abstract: A method of treating a TNF Alpha associated medical condition selected from the group consisting of obesity, metabolic syndrome, diabetes and a liver disease or disorder is provided. The method comprising enterally administering to a subject in need thereof a therapeutically effective amount of plant cells expressing a TNF Alpha polypeptide inhibitor, thereby treating the TNF Alpha associated medical condition.
Abstract translation: 提供了一种治疗选自肥胖症，代谢综合征，糖尿病和肝病或病症的TNFα相关医学病症的方法。 该方法包括向有需要的受试者肠道施用治疗有效量的表达TNFα多肽抑制剂的植物细胞，从而治疗TNFα相关的医学病症。
-
10.发明授权公开(公告)号：US09220737B2
公开(公告)日：2015-12-29
申请号：US14292966
申请日：2014-06-02
Applicant: Protalix Ltd.
Inventor： Yoseph Shaaltiel , Gideon Baum , Daniel Bartfeld , Sharon Hashmueli , Ayala Lewkowicz
CPC classification number: A61K38/47 , A61K9/0053 , A61K36/23 , C07K2319/04 , C12N9/2405 , C12N9/2434 , C12N9/2465 , C12N15/8257 , C12P21/005 , C12Y302/01022 , C12Y302/01045
Abstract: A device, system and method for producing glycosylated proteins in plant culture, particularly proteins having a high mannose glycosylation, while targeting such proteins with an ER signal and/or by-passing the Golgi. The invention further relates to vectors and methods for expression and production of enzymatically active high mannose lysosomal enzymes using transgenic plant root, particularly carrot cells. More particularly, the invention relates to host cells, particularly transgenic suspended carrot cells, vectors and methods for high yield expression and production of biologically active high mannose Glucocerebrosidase (GCD). The invention further provides for compositions and methods for the treatment of lysosomal storage diseases.
Abstract translation: 用于在植物培养物中生产糖基化蛋白质的装置，系统和方法，特别是具有高甘露糖糖基化的蛋白质，同时用ER信号靶向这种蛋白质和/或旁路高尔基体。 本发明进一步涉及使用转基因植物根特别是胡萝卜细胞表达和产生酶活性高甘露糖溶酶体酶的载体和方法。 更具体地，本发明涉及宿主细胞，特别是转基因悬浮的胡萝卜细胞，用于高产量表达和生产生物活性高甘露糖葡糖脑苷脂酶（GCD）的载体和方法。 本发明还提供了用于治疗溶酶体贮积病的组合物和方法。
-
-
-
-
-
-
-
-
-
Search Results
39
records
(took 0.023 seconds)
